Eris Lifesciences is one of the leading mid-sized domestic pharmaceutical companies in India. The Company has established itself as a credible top 40 player in the domestic formulations industry. Eris Lifesciences has a sharp focus on the chronic and lifestyle diseases segment.
Founded in 2001, GVK BIO is one of Asia’s leading providers of integrated contract research and manufacturing services. The Company provides small and large molecule discovery services, custom chemical synthesis manufacturing and informatics services to large global pharmaceutical, biotechnology and agrochemical companies.
Intas is one of the fastest growing domestic pharmaceutical companies in India and is amongst the largest companies in the industry. The Company has a diversified product portfolio focused on chronic segments. Intas has also built up a sizable export business focused on the regulated pharmaceutical markets.
Ipca Laboratories (“IPCA”) is an integrated pharmaceuticals player producing both domestic formulations and active pharmaceutical ingredients. The Company also serves the regulated and unregulated export markets. In addition, IPCA is also an established player in the anti-malarial institutional market.
Torrent Pharmaceuticals is a large pharmaceuticals player with a presence in both the domestic and export formulations market. The Company is amongst the top 15 players in India, with a chronic focused basket of formulation products. Torrent Pharmaceuticals also exports products to key markets including the U.S., Brazil and Europe.
Mankind Pharmaceuticals is amongst the fastest growing domestic pharmaceutical companies in India and is the fifth largest domestic player currently. The Company initially differentiated itself with a unique strategy of targeting rural and semi-urban cities and building a large share of lower value prescriptions across India but this strategy has evolved over time to now cover the entire country.
Cadila is the one of the largest domestic pharmaceutical companies with a focus on the formulations market. The Company is strong in the cardiovascular, female healthcare and gastrointestinal therapeutic areas. Cadila has also built a strong position in regulated markets such as the U.S. and France and in emerging markets such as Brazil, South Africa and Russia.